MBX NASDAQ
MBX Biosciences, Inc. Common Stock
1W: -1.0%
1M: -7.9%
3M: -17.2%
YTD: +73.4%
1Y: +211.6%
$52.97
+2.68 (+5.33%)
Pre-Market: $55.81 (+2.84, +5.37%)
Weekly Expected Move ±8.3%
$40
$44
$48
$53
$57
Credit Risk of going bust: lower than 78% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), MBX Biosciences, Inc. Common Stock would be worth roughly what it owes.
Total debt $3.3M against a stock market value of $2.55B.
Distance to default 9.21 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 76.9%; Altman Z'' 18.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), MBX Biosciences, Inc. Common Stock would be worth roughly what it owes.
Total debt $3.3M against a stock market value of $2.55B.
Distance to default 9.21 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 76.9%; Altman Z'' 18.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Oppenheimer's top 50 small- and mid-cap Buy list
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE
Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
12 Health Care Stocks Moving In Friday's Pre-Market Session
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
The Technical Signals Behind (MBX) That Institutions Follow - Stock Traders Daily
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
[144] MBX Biosciences, Inc. SEC Filing - Stock Titan
MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan
MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan
MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade (NASDAQ:MBX) - Seeking Alpha
MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan
MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan
MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan
MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan
MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan
MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan
MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan
Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - simplywall.st
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
Once-weekly canvuparatide Phase 2 data set for ENDO 2026 call - Stock Titan
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - The Motley Fool
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
MBX Biosciences leaders to present at New York Jefferies healthcare event - Stock Titan
Insider Stock Buying Reaches US$1.06m On MBX Biosciences
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences Highlights Positive Phase 1 Obesity Data - TipRanks
MBX Biosciences reports early obesity drug trial data By Investing.com - Investing.com Canada
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX obesity drug targets monthly dosing after 7% Phase 1 weight loss - Stock Titan
Brokers Set Expectations for MBX Biosciences Q1 Earnings - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Momentum - Sahm
Trading the Move, Not the Narrative: (MBX) Edition - Stock Traders Daily
Wall Street Zen Upgrades MBX Biosciences (NASDAQ:MBX) to Hold - MarketBeat
MBX SEC Filings - MBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Top MBX Biosciences Executive Makes Notable Stock Move - TipRanks
Mbx Biosciences CEO Hawryluk sells $17,930 in stock - Investing.com
MBX Biosciences (NASDAQ: MBX) CMO sells 231 shares to cover RSU tax obligations - Stock Titan
Catalyst Watch: Cerebras headlines AI-related IPO blitz, CPI print and 13Fs
MBX Biosciences (NASDAQ:MBX) Shares Up 12% - What's Next? - MarketBeat
Is MBX Biosciences’ (MBX) Narrower Loss and Director Equity Grants Reframing Its Risk‑Reward Story? - simplywall.st
MBX Biosciences (NASDAQ: MBX) posts Q1 loss, cash funding plans into 2029 - Stock Titan
MBX Biosciences (NASDAQ: MBX) details Q1 loss and $440M cash - Stock Titan
MBX lines up obesity data, says $440M can fund operations into 2029 - Stock Titan
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award - markets.businessinsider.com
Why is MBX Biosciences' new CBO appointment so significant for investors - Kavout
3 Overlooked Stocks Set to Soar in 2026
3 Overlooked Stocks Set to Soar in 2026
MBX Biosciences (NASDAQ: MBX) director awarded RSUs and 74,249 stock options - Stock Titan
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX to detail obesity drug pipeline at May 11 online, in-person event - Stock Titan
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed - Quiver Quantitative
MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed - Quiver Quantitative
Microbix Engages with Diagnostics Industry Experts
Microbix Presenting at the 2026 Bloom Burton Conference
Microbix Exhibiting & Presenting at ESCMID Global 2026
Aaron Wealth Advisors LLC Buys 20,000 Shares of MBX Biosciences, Inc. $MBX
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
Microbix Announces Annual Meeting Voting Results
Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX
Microbix Presents Reference-Material Innovations at EUROGIN
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus
MBX Biosciences GAAP EPS of -$0.49
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences CFO Shift Puts Funding And Execution In Focus
MBX Biosciences to Participate in Upcoming March Investor Conferences
Microbix Biosystems Q1 Earnings Call Highlights
Microbix Reports Results for Q1 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
Microbix Biosystems (TSE:MBX) Share Price Passes Below 50-Day Moving Average – Time to Sell?
Microbix Presents Molecular Pathology Platform Results
Martin Marino Purchases 52,500 Shares of Microbix Biosystems (TSE:MBX) Stock
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference